BCL2 and breast carcinoma: In TNBC, Deng et al. revealed that miR-34a was co-encapsulated with doxorubicin into hyaluronic acid (HA)–chitosan (CS) nanoparticles, and delivered into breast cancer cells synchronously to enhance antitumor effects by suppressing Bcl-2.